View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsWellbiotec 배당 및 자사주 매입배당 기준 점검 0/6Wellbiotec 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률1,899.7%자사주 매입 수익률총 주주 수익률1,899.7%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesBoard Change • Jan 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Internal Director Choon-Jae Park was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • Mar 18Wellbiotec Co., Ltd., Annual General Meeting, Mar 31, 2025Wellbiotec Co., Ltd., Annual General Meeting, Mar 31, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 17, yeongdong-daero 106-gil, gangnam-gu, seoul South KoreaReported Earnings • Apr 10Full year 2023 earnings released: ₩820 loss per share (vs ₩325 loss in FY 2022)Full year 2023 results: ₩820 loss per share (further deteriorated from ₩325 loss in FY 2022). Revenue: ₩72.1b (down 54% from FY 2022). Net loss: ₩64.9b (loss widened 211% from FY 2022). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.New Risk • Apr 05New major risk - Revenue and earnings growthEarnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 13% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (37% increase in shares outstanding). Market cap is less than US$100m (₩53.2b market cap, or US$39.4m).분석 기사 • Mar 22Take Care Before Jumping Onto Wellbiotec Co., Ltd. (KRX:010600) Even Though It's 28% CheaperTo the annoyance of some shareholders, Wellbiotec Co., Ltd. ( KRX:010600 ) shares are down a considerable 28% in the...New Risk • Nov 01New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩134.6b (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 0.8% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (37% increase in shares outstanding). Market cap is less than US$100m (₩134.6b market cap, or US$99.1m).공시 • Jun 14Wellbiotec Co., Ltd. announced that it has received KRW 8.00000001 billion in funding from K-Impact FundOn June 13, 2023, Wellbiotec Co., Ltd. closed the transaction.Reported Earnings • May 18First quarter 2023 earnings released: ₩8.00 loss per share (vs ₩63.00 profit in 1Q 2022)First quarter 2023 results: ₩8.00 loss per share (down from ₩63.00 profit in 1Q 2022). Revenue: ₩26.5b (down 57% from 1Q 2022). Net loss: ₩520.6m (down 114% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 26Full year 2022 earnings released: ₩98.00 loss per share (vs ₩383 loss in FY 2021)Full year 2022 results: ₩98.00 loss per share (improved from ₩383 loss in FY 2021). Revenue: ₩190.9b (up 57% from FY 2021). Net loss: ₩6.28b (loss narrowed 70% from FY 2021). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.공시 • Feb 08Wellbiotec Co., Ltd. announced that it expects to receive KRW 10 billion in funding from Sangsangin Plus Savings Bank Co.,Ltd., Sangsangin Savings Bank, Investment ArmWellbiotec Co., Ltd. announced a private placement of series 32 Unsecured privately placed convertible bonds with bearer interest for the gross proceeds of KRW 10,000,000,000 on February 7, 2023. The transaction will include participation from retuning investor Sangsangin Savings Bank, Investment Arm and Sangsangin Plus Savings Bank Co.,Ltd. for KRW 5,000,000,000 each. The bonds are 100% convertible into 8,841,732 shares at a fixed conversion price of KRW 1,131 per share from February 9, 2024 to January 09, 2026. The bonds bear 3% interest rate and 8% yield to maturity and will mature on February 9, 2026. The transaction has been approved by the board of directors and is expected to close on February 9, 2023. The bonds are restricted to a hold period of one year from the date of issuance.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Internal Director Choon-Jae Park was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • Jun 22Wellbiotec Co., Ltd. announced that it expects to receive KRW 3 billion in funding from KH Feelux Co., Ltd.Wellbiotec Co., Ltd. announced a private placement of 31st series no-guaranteed Private convertible bonds with barer type interest part convertible bonds for gross proceeds of KRW 3,000,000,000 on June 21, 2022. The transaction included participation from new investor KH Feelux Co., Ltd. The bonds are having coupon rate 5% and will mature on June 22, 2025. The bonds will be 100% convertible into 1,951,854 common shares of the company at a fixed conversion price of KRW 1,537 per share from June 22, 2023 to May 25, 2025. The board of directors of the company approved the transaction. The subscription and payment date are June 22, 2022.Reported Earnings • May 18First quarter 2022 earnings released: EPS: ₩63.00 (vs ₩44.00 loss in 1Q 2021)First quarter 2022 results: EPS: ₩63.00 (up from ₩44.00 loss in 1Q 2021). Revenue: ₩62.1b (up 262% from 1Q 2021). Net income: ₩3.68b (up ₩5.76b from 1Q 2021). Profit margin: 5.9% (up from net loss in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 17% per year whereas the company’s share price has fallen by 14% per year.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Internal Director Choon-Jae Park was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공시 • Apr 16Wellbiotec Co., Ltd. announced that it expects to receive KRW 10 billion in funding from Wise Pacific Holdings LimitedWellbiotec Co., Ltd. (KOSE:A010600) announced a private placement of round 29th and 30th non-guaranteed private equity convertible bonds with bearer interest for gross proceeds of KRW 10,000,000,000 on April 14, 2021. The transaction will include participation from Rover Holdings Co., Ltd. and returning investor Wise Pacific Holdings Limited for KRW 5,000,000,000 each. The bond is issued at maturity interest rate of 4% and surface interest rate of 0%. The 29th bond will mature on May 14, 2024 and 30th bond will mature on June 14, 2024. The bonds will be 100% convertible into 2,833,662 common shares at a fixed conversion price of KRW 3,529 per share. The 29th bonds will convert from May 14, 2022 to April 14, 2024 and 30th bonds will convert from June 14, 2022 to May 14, 2024. The board of directors of the company approved the transaction. The payment date for 29th bonds is May 14, 2021 and 30th bonds is June 14, 2021.The bonds issued in the transaction will have a hold period of one year from the date of issuance.공시 • Mar 11Wellbiotec Co., Ltd., Annual General Meeting, Mar 30, 2021Wellbiotec Co., Ltd., Annual General Meeting, Mar 30, 2021, at 09:00 Korea Standard Time.공시 • Feb 27+ 2 more updatesWellbiotec Co., Ltd. announced that it has received KRW 15 billion in funding from Sangsangin Savings Bank, Investment Arm, Sangsangin Plus Savings Bank, Investment ArmOn February 26, 2021, Wellbiotec Co., Ltd. (KOSE:A010600) closed the transaction.Is New 90 Day High Low • Feb 26New 90-day high: ₩2,955The company is up 28% from its price of ₩2,300 on 27 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Luxury industry, which is up 20% over the same period.Is New 90 Day High Low • Jan 22New 90-day high: ₩2,780The company is up 29% from its price of ₩2,155 on 23 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Luxury industry, which is up 11% over the same period.Is New 90 Day High Low • Jan 05New 90-day high: ₩2,660The company is up 17% from its price of ₩2,275 on 07 October 2020. The South Korean market is up 23% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Luxury industry, which is up 8.0% over the same period.Is New 90 Day High Low • Dec 15New 90-day high: ₩2,550The company is up 3.0% from its price of ₩2,470 on 16 September 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 5.0% over the same period.분석 기사 • Dec 11Here's Why Wellbiotec (KRX:010600) Can Afford Some DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Is New 90 Day High Low • Oct 26New 90-day low: ₩2,060The company is down 41% from its price of ₩3,480 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 14% over the same period.Is New 90 Day High Low • Oct 08New 90-day low: ₩2,215The company is down 23% from its price of ₩2,875 on 10 July 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 6.0% over the same period.공시 • Aug 27Wellbiotec Co., Ltd. (KOSE:A010600) agreed to acquire Kumyoungeng Co., Ltd from Seungho Choi for KRW 35 billion.Wellbiotec Co., Ltd. (KOSE:A010600) agreed to acquire Kumyoungeng Co., Ltd from Seungho Choi for KRW 35 billion on August 25, 2020. Wellbiotec Co., Ltd. will acquire 0.05 million shares of Kumyoungeng Co., Ltd. Wellbiotec Co., Ltd. shall pay KRW 2.5 billion as down payment on the contract date, KRW 17.5 billion on October 7, 2020 and balance of KRW 15 billion on November 6, 2020. For the period ending December 2019, Kumyoungeng Co., Ltd reported total assets of KRW 27.75 billion, total equity of KRW 15.86 billion, sales of KRW 50.29 billion and net income of KRW 3.72 billion. The transaction is expected to complete on November 6, 2020.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 A010600 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: A010600 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Wellbiotec 배당 수익률 vs 시장A010600의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (A010600)n/a시장 하위 25% (KR)1.0%시장 상위 25% (KR)3.7%업계 평균 (Luxury)3.0%분석가 예측 (A010600) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 A010600 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 A010600 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 A010600 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: A010600 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YKR 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/01/27 04:02종가2026/01/23 00:00수익2025/09/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Wellbiotec Co., Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Board Change • Jan 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Internal Director Choon-Jae Park was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • Mar 18Wellbiotec Co., Ltd., Annual General Meeting, Mar 31, 2025Wellbiotec Co., Ltd., Annual General Meeting, Mar 31, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 17, yeongdong-daero 106-gil, gangnam-gu, seoul South Korea
Reported Earnings • Apr 10Full year 2023 earnings released: ₩820 loss per share (vs ₩325 loss in FY 2022)Full year 2023 results: ₩820 loss per share (further deteriorated from ₩325 loss in FY 2022). Revenue: ₩72.1b (down 54% from FY 2022). Net loss: ₩64.9b (loss widened 211% from FY 2022). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings.
New Risk • Apr 05New major risk - Revenue and earnings growthEarnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 13% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (37% increase in shares outstanding). Market cap is less than US$100m (₩53.2b market cap, or US$39.4m).
분석 기사 • Mar 22Take Care Before Jumping Onto Wellbiotec Co., Ltd. (KRX:010600) Even Though It's 28% CheaperTo the annoyance of some shareholders, Wellbiotec Co., Ltd. ( KRX:010600 ) shares are down a considerable 28% in the...
New Risk • Nov 01New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩134.6b (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 0.8% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (37% increase in shares outstanding). Market cap is less than US$100m (₩134.6b market cap, or US$99.1m).
공시 • Jun 14Wellbiotec Co., Ltd. announced that it has received KRW 8.00000001 billion in funding from K-Impact FundOn June 13, 2023, Wellbiotec Co., Ltd. closed the transaction.
Reported Earnings • May 18First quarter 2023 earnings released: ₩8.00 loss per share (vs ₩63.00 profit in 1Q 2022)First quarter 2023 results: ₩8.00 loss per share (down from ₩63.00 profit in 1Q 2022). Revenue: ₩26.5b (down 57% from 1Q 2022). Net loss: ₩520.6m (down 114% from profit in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 26Full year 2022 earnings released: ₩98.00 loss per share (vs ₩383 loss in FY 2021)Full year 2022 results: ₩98.00 loss per share (improved from ₩383 loss in FY 2021). Revenue: ₩190.9b (up 57% from FY 2021). Net loss: ₩6.28b (loss narrowed 70% from FY 2021). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings.
공시 • Feb 08Wellbiotec Co., Ltd. announced that it expects to receive KRW 10 billion in funding from Sangsangin Plus Savings Bank Co.,Ltd., Sangsangin Savings Bank, Investment ArmWellbiotec Co., Ltd. announced a private placement of series 32 Unsecured privately placed convertible bonds with bearer interest for the gross proceeds of KRW 10,000,000,000 on February 7, 2023. The transaction will include participation from retuning investor Sangsangin Savings Bank, Investment Arm and Sangsangin Plus Savings Bank Co.,Ltd. for KRW 5,000,000,000 each. The bonds are 100% convertible into 8,841,732 shares at a fixed conversion price of KRW 1,131 per share from February 9, 2024 to January 09, 2026. The bonds bear 3% interest rate and 8% yield to maturity and will mature on February 9, 2026. The transaction has been approved by the board of directors and is expected to close on February 9, 2023. The bonds are restricted to a hold period of one year from the date of issuance.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Internal Director Choon-Jae Park was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • Jun 22Wellbiotec Co., Ltd. announced that it expects to receive KRW 3 billion in funding from KH Feelux Co., Ltd.Wellbiotec Co., Ltd. announced a private placement of 31st series no-guaranteed Private convertible bonds with barer type interest part convertible bonds for gross proceeds of KRW 3,000,000,000 on June 21, 2022. The transaction included participation from new investor KH Feelux Co., Ltd. The bonds are having coupon rate 5% and will mature on June 22, 2025. The bonds will be 100% convertible into 1,951,854 common shares of the company at a fixed conversion price of KRW 1,537 per share from June 22, 2023 to May 25, 2025. The board of directors of the company approved the transaction. The subscription and payment date are June 22, 2022.
Reported Earnings • May 18First quarter 2022 earnings released: EPS: ₩63.00 (vs ₩44.00 loss in 1Q 2021)First quarter 2022 results: EPS: ₩63.00 (up from ₩44.00 loss in 1Q 2021). Revenue: ₩62.1b (up 262% from 1Q 2021). Net income: ₩3.68b (up ₩5.76b from 1Q 2021). Profit margin: 5.9% (up from net loss in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 17% per year whereas the company’s share price has fallen by 14% per year.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. 1 independent director (3 non-independent directors). Internal Director Choon-Jae Park was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공시 • Apr 16Wellbiotec Co., Ltd. announced that it expects to receive KRW 10 billion in funding from Wise Pacific Holdings LimitedWellbiotec Co., Ltd. (KOSE:A010600) announced a private placement of round 29th and 30th non-guaranteed private equity convertible bonds with bearer interest for gross proceeds of KRW 10,000,000,000 on April 14, 2021. The transaction will include participation from Rover Holdings Co., Ltd. and returning investor Wise Pacific Holdings Limited for KRW 5,000,000,000 each. The bond is issued at maturity interest rate of 4% and surface interest rate of 0%. The 29th bond will mature on May 14, 2024 and 30th bond will mature on June 14, 2024. The bonds will be 100% convertible into 2,833,662 common shares at a fixed conversion price of KRW 3,529 per share. The 29th bonds will convert from May 14, 2022 to April 14, 2024 and 30th bonds will convert from June 14, 2022 to May 14, 2024. The board of directors of the company approved the transaction. The payment date for 29th bonds is May 14, 2021 and 30th bonds is June 14, 2021.The bonds issued in the transaction will have a hold period of one year from the date of issuance.
공시 • Mar 11Wellbiotec Co., Ltd., Annual General Meeting, Mar 30, 2021Wellbiotec Co., Ltd., Annual General Meeting, Mar 30, 2021, at 09:00 Korea Standard Time.
공시 • Feb 27+ 2 more updatesWellbiotec Co., Ltd. announced that it has received KRW 15 billion in funding from Sangsangin Savings Bank, Investment Arm, Sangsangin Plus Savings Bank, Investment ArmOn February 26, 2021, Wellbiotec Co., Ltd. (KOSE:A010600) closed the transaction.
Is New 90 Day High Low • Feb 26New 90-day high: ₩2,955The company is up 28% from its price of ₩2,300 on 27 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Luxury industry, which is up 20% over the same period.
Is New 90 Day High Low • Jan 22New 90-day high: ₩2,780The company is up 29% from its price of ₩2,155 on 23 October 2020. The South Korean market is up 32% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Luxury industry, which is up 11% over the same period.
Is New 90 Day High Low • Jan 05New 90-day high: ₩2,660The company is up 17% from its price of ₩2,275 on 07 October 2020. The South Korean market is up 23% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Luxury industry, which is up 8.0% over the same period.
Is New 90 Day High Low • Dec 15New 90-day high: ₩2,550The company is up 3.0% from its price of ₩2,470 on 16 September 2020. The South Korean market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 5.0% over the same period.
분석 기사 • Dec 11Here's Why Wellbiotec (KRX:010600) Can Afford Some DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Is New 90 Day High Low • Oct 26New 90-day low: ₩2,060The company is down 41% from its price of ₩3,480 on 28 July 2020. The South Korean market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 14% over the same period.
Is New 90 Day High Low • Oct 08New 90-day low: ₩2,215The company is down 23% from its price of ₩2,875 on 10 July 2020. The South Korean market is up 11% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 6.0% over the same period.
공시 • Aug 27Wellbiotec Co., Ltd. (KOSE:A010600) agreed to acquire Kumyoungeng Co., Ltd from Seungho Choi for KRW 35 billion.Wellbiotec Co., Ltd. (KOSE:A010600) agreed to acquire Kumyoungeng Co., Ltd from Seungho Choi for KRW 35 billion on August 25, 2020. Wellbiotec Co., Ltd. will acquire 0.05 million shares of Kumyoungeng Co., Ltd. Wellbiotec Co., Ltd. shall pay KRW 2.5 billion as down payment on the contract date, KRW 17.5 billion on October 7, 2020 and balance of KRW 15 billion on November 6, 2020. For the period ending December 2019, Kumyoungeng Co., Ltd reported total assets of KRW 27.75 billion, total equity of KRW 15.86 billion, sales of KRW 50.29 billion and net income of KRW 3.72 billion. The transaction is expected to complete on November 6, 2020.